See more : Triton Development S.A. (TRI.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Neuropathix, Inc. (NPTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neuropathix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nippon Pillar Packing Co., Ltd. (6490.T) Income Statement Analysis – Financial Results
- Prismaflex International, S.A. (ALPRI.PA) Income Statement Analysis – Financial Results
- Gulf Island Fabrication, Inc. (GIFI) Income Statement Analysis – Financial Results
- Enthusiast Gaming Holdings Inc. (EGLX) Income Statement Analysis – Financial Results
- Far East Holdings International Limited (0036.HK) Income Statement Analysis – Financial Results
Neuropathix, Inc. (NPTX)
About Neuropathix, Inc.
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|
| Revenue | 183.48B | 0.00 | 126.03K | 173.89K | 1.15K | 34.97K | 145.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.00K | 51.00K |
| Gross Profit | 183.48B | 0.00 | 126.03K | 173.89K | 1.15K | 13.97K | 94.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 39.95% | 64.83% |
| Research & Development | 451.78K | 1.10M | 554.70K | 224.93K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.67M | 3.38M | 1.90M | 1.01M | 23.60K | 30.26K | 37.93K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.73K | 51.33K |
| SG&A | 2.67M | 3.38M | 1.90M | 1.01M | 23.60K | 45.99K | 89.26K |
| Other Expenses | -183.48K | 108.19K | 0.00 | 3.94M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.94M | 4.47M | 2.46M | 1.24M | 23.60K | 45.99K | 89.26K |
| Cost & Expenses | 2.94M | 4.47M | 2.46M | 1.24M | 23.60K | 66.99K | 140.26K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 434.59K | 924.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 21.07K | 124.32K | 980.35K | 2.81M | 52.52K | 22.82K | 0.00 |
| EBITDA | -2.92M | -4.35M | -1.35M | 40.73K | -22.44K | -32.02K | 4.74K |
| EBITDA Ratio | 0.00% | 0.00% | -1,070.22% | 23.43% | -1,944.80% | -91.58% | 3.27% |
| Operating Income | -2.94M | -4.47M | -2.33M | -1.06M | -22.44K | -32.02K | 4.74K |
| Operating Income Ratio | 0.00% | 0.00% | -1,848.11% | -610.62% | -1,944.80% | -91.58% | 3.27% |
| Total Other Income/Expenses | 2,940.63B | -63.55K | -1.12M | 2.80M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -3.56M | -4.54M | -3.45M | 1.74M | -22.44K | -32.02K | 4.74K |
| Income Before Tax Ratio | 0.00% | 0.00% | -2,738.19% | 1,002.39% | -1,944.80% | -91.58% | 3.27% |
| Income Tax Expense | 434.59K | 1.03M | 1.11M | 811.98K | 0.00 | 0.00 | 0.00 |
| Net Income | -3.99M | -5.57M | -4.57M | 936.82K | -22.44K | -32.02K | 4.74K |
| Net Income Ratio | 0.00% | 0.00% | -3,622.86% | 538.74% | -1,944.80% | -91.58% | 3.27% |
| EPS | -0.05 | -0.07 | -0.06 | 0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.05 | -0.07 | -0.06 | 0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 87.58M | 74.62M | 71.23M | 68.85M | 48.50M | 9.53M | 9.53M |
| Weighted Avg Shares Out (Dil) | 87.58M | 74.62M | 71.23M | 68.85M | 48.50M | 9.53M | 9.53M |
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
Source: https://incomestatements.info
Category: Stock Reports